Fig. 4From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experienceForest plot of the association between cytoreductive radiotherapy before abiraterone failure and overall survival by subgroup. HR hazard ratio, 95% CI 95% confidence intervalBack to article page